Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proof of principle for iPS2-10X-seq: timecourse experiment during 2D cardiac differentiation

ABSTRACT: Proof of principle for iPS2-10X-seq: timecourse experiment during 2D cardiac differentiation

PROVIDER: PRJEB75579 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR13071619_1.fastq.gz	Fastqsanger.gz
	ERR13071619_2.fastq.gz	Fastqsanger.gz
	ERR13071620_1.fastq.gz	Fastqsanger.gz
	ERR13071620_2.fastq.gz	Fastqsanger.gz
	ERR13071621_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 32

Similar Datasets

Proof of principle for iPS2-10X-seq: cardioids experiment during 3D cardiac differentiation

Project description:Proof of principle for iPS2-10X-seq: cardioids experiment during 3D cardiac differentiation

| PRJEB75583 | ENA

P. vivax: proof-of-principle global transcription analysis from two wild isolates

Project description:The complete genome sequence of the P. vivax Sal-1 strain allowed the design of a first version array representing 1 oligo/2 kb of coding sequences (http://zblab.sbs.ntu.edu.sg/vivax/index.html). Here, proof-of-principle experiments using total RNA of parasites obtained from the Sal-1 strain, from P. falciparum and from parasites obtained directly from two human patients are presented. To determine the extent of cross-hybridization of P. falciparum with P. vivax, and to determine overlaps in expression profiles of the P. vivax Sal1 monkey-adapted strain vs wild isolates, single dual hybridization analyses were performed.

2008-04-12 | E-GEOD-11075 | biostudies-arrayexpress

Pre-clinical proof of principle for orally delivered Th17 antagonist miniproteins

Project description:Pre-clinical proof of principle for orally delivered Th17 antagonist miniproteins

| PRJNA1096346 | ENA

P. vivax: proof-of-principle global transcription analysis from two wild isolates

2008-04-12 | GSE11075 | GEO

P. vivax: proof-of-principle global transcription analysis from two wild isolates

Project description:P. vivax: proof-of-principle global transcription analysis from two wild isolates

| PRJNA107065 | ENA

C3PO applied to spatial transcriptomics - 1D and 2D gridmode sequence data

Project description:Raw sequencing data for the proof-of-principal 1D and 2D gridmode transcriptomics performed after C3PO in the following article: https://www.biorxiv.org/content/10.1101/2024.03.12.584578v1.full. The 1D data is found in the limb68 samples here (limb #3 in the article) and the 2 replicates of the 2D data is found in the L127 samples (limb #4 in the article) and L128 samples (limb #5 in the article). For the 2D data the P# value in the filename indicates the corresponding FACS gate.

2025-03-10 | E-MTAB-14936 | biostudies-arrayexpress

Characterisation of dysplastic liver nodules using low-pass sequencing and the proof of principle on liquid biopsies

Project description:Characterisation of dysplastic liver nodules using low-pass sequencing and the proof of principle on liquid biopsies

| PRJEB20592 | ENA

Identifying novel surface markers for megakaryocyte progenitor cells [10x timecourse]

Project description:We carried out 10X sequencing of a timecourse of human induced pluripotent stem cells over a course of 20 days as they differentiated towards megakaryocytes.

2022-02-23 | GSE160604 | GEO

Project description:ChAMP proof of principle

| PRJNA1041053 | ENA

A new strategy for identifying mechanisms of drug-drug interaction using transcriptome analysis: Compound Kushen injection as a proof of principle

Project description:Drug-drug interactions (DDIs), especially with herbal medicines, are complex, making it difficult to identify potential molecular mechanisms and targets. We introduce a workflow to carry out DDI research using transcriptome analysis and interactions of a complex herbal mixture, Compound Kushen Injection (CKI), with cancer chemotherapy drugs, as a proof of principle. Using CKI combined with doxorubicin or 5-Fu on cancer cells as a model, we found that CKI enhanced the cytotoxic effects of doxorubicin on A431 cells while protecting MDA-MB-231 cells treated with 5-Fu. We generated and analysed transcriptome data from cells treated with single treatments or combined treatments and our analysis showed that opposite directions of regulation for pathways related to DNA synthesis and metabolism appeared to be the main reason for different effects of CKI when used in combination with chemotherapy drugs . We also found that pathways related to organic biosynthetic and metabolic processes might be potential targets for CKI when interacting with doxorubicin and 5-Fu. Through co-expression analysis correlated with phenotype results, we selected the MYD88 gene as a candidate major regulator for validation as a proof of concept for our approach. Inhibition of MYD88 reduced antagonistic cytotoxic effects between CKI and 5-Fu, indicating that MYD88 is an important gene in the DDI mechanism between CKI and chemotherapy drugs. These findings demonstrate that our pipeline is effective for the application of transcriptome analysis to the study of DDIs in order to identify candidate mechanisms and potential targets.

2019-08-20 | GSE130359 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data